A Phase 2 trial of gantenerumab, an experimental antibody treatment for early Alzheimer’s disease, is being expanded with a view to preparing for registration, MorphoSys AG announced. The trial is being conducted by Roche. ---Subscribe to MedNous to access this article--- Company News Clinical Research
